Tech

In Fight Against Pancreatic Cancer, Daraxonrasib Is Rare Sign Of Hope

FORBES·2h ago·3 min read

Photograph via Forbes

RSS SUMMARY · AGGREGATED FROM FORBES

The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major advance against metastatic pancreatic cancer.

The full story continues on Forbes.

Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.

Read on Forbes →

The Source

The full story continues on Forbes.

FORBES

​The Hidden Intake Gap: Why ABA Referral Conversion Fails Before The First Visit

Here’s Everything Coming To Destiny 2’s Final June 9 Update

Snowflake CEO Says ‘Better Be Paranoid Than Confident’ About SaaSpocalypse

Redefining Time To Value When AI Does The Work For You

On this beat

Mainframe modernization is about trust, not migration

​The Hidden Intake Gap: Why ABA Referral Conversion Fails Before The First Visit

Here are the IMAX theaters that can play ‘The Odyssey’ in true 70mm

Nintendo will pay a $40 million fine for faulty Joy-Cons

The Hidden Intake Gap: Why ABA Referral Conversion Fails Before The First Visit

The Hidden Intake Gap: Why ABA Referral Conversion Fails Before The First Visit